Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents

BACKGROUND: Neisseria meningitidis serogroup B (MnB) is a leading cause of invasive meningococcal disease in adolescents and young adults. A recombinant factor H binding protein (fHBP) vaccine (Trumenba(®); bivalent rLP2086) was recently approved in the United States in individuals aged 10–25 years....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Pediatric Infect Dis Soc
Main Authors: Vesikari, Timo, Østergaard, Lars, Diez-Domingo, Javier, Wysocki, Jacek, Flodmark, Carl-Erik, Beeslaar, Johannes, Eiden, Joseph, Jiang, Qin, Jansen, Kathrin U., Jones, Thomas R., Harris, Shannon L., O'Neill, Robert E., York, Laura J., Crowther, Graham, Perez, John L.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2016
Assuntos:
Original Articles and Commentaries
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5407127/
https://ncbi.nlm.nih.gov/pubmed/26407272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jpids/piv039
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados